LOS ANGELES, March 29, 2005 (PRIMEZONE) -- SmallcapInsights.com, www.SmallcapInsights.com, the online source for exclusive commentary, research, interviews and other key investor information, has announced the availability of an audio interview with Michael Weiner, CEO of Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology.
In the audio interview with SmallcapInsights.com, Mr. Weiner explained the importance of the recent issued patents and patent applications. Biophan's growing intellectual property portfolio now consists of 114 patents, licenses or applications, in technology areas such as nanotechnology, photonics and others. That total now includes a new total of 34 patents issued, with eight recently allowed applications and 72 pending applications at various stages of examination. Biophan is leveraging its extensive intellectual property to capitalize on opportunities in several multi-billion-dollar biomedical markets, including drug-delivery systems and the creation of implantable medical devices, such as stents and catheters, that are safe and image-compatible with Magnetic Resonance Imaging (MRI) systems.
The streaming audio interview can be accessed at http://www.SmallcapInsights.com. Registration to listen to the interview is free.
About Smallcap Insights
Smallcap Insights provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. Smallcap Insights strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on SmallcapInsights.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at www.SmallcapInsights.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 34 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Compensation and Other Disclosures
Smallcap Insights is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by Smallcap Insights are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from Biophan of $12,500 per month through February 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. A subsidiary of Trilogy has entered into an agreement with a non-affiliate shareholder of this company pursuant to which the subsidiary has agreed to purchase from time to time from the third party under certain conditions up to an aggregate of 6,380,000 shares of common stock of this company at prices ranging from $.60 to $2.00 per share.